Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $939000.0.

  • Anika Therapeutics' Tax Provisions fell 5731.82% to $939000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 6632.98%. This contributed to the annual value of $6.1 million for FY2024, which is 805.16% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Tax Provisions is $939000.0, which was down 5731.82% from $700000.0 recorded in Q2 2025.
  • Anika Therapeutics' 5-year Tax Provisions high stood at $9.1 million for Q4 2023, and its period low was -$3.4 million during Q4 2021.
  • Over the past 5 years, Anika Therapeutics' median Tax Provisions value was $100000.0 (recorded in 2025), while the average stood at $886105.3.
  • Per our database at Business Quant, Anika Therapeutics' Tax Provisions tumbled by 27142.86% in 2022 and then soared by 54000.0% in 2024.
  • Over the past 5 years, Anika Therapeutics' Tax Provisions (Quarter) stood at -$3.4 million in 2021, then surged by 293.98% to $6.6 million in 2022, then soared by 37.62% to $9.1 million in 2023, then plummeted by 72.24% to $2.5 million in 2024, then tumbled by 62.81% to $939000.0 in 2025.
  • Its Tax Provisions was $939000.0 in Q3 2025, compared to $700000.0 in Q2 2025 and $100000.0 in Q1 2025.